


Prevalence of symptoms in patients with Morquio A (MPS IVA)^{1,a}



Adapted from Harmatz, *Mol Genet Metab*, 2013.

Abbreviations: ENT, ear, nose, and throat; MPS, mucopolysaccharidosis.

^a 25% of patients with Morquio A are classified as nonclassical.

^b Percentages reflect prevalence of symptoms in 325 patients as reported in the Morquio A Clinical Assessment Program study.

^c The range indicated refers to the incidence of cardiac valve regurgitation in adult patients (n=69; 28% mitral, 32% tricuspid, 39% aortic).

^d The range indicated refers to the incidence of reported spinal abnormalities (65% odontoid dysplasia, 49% cervical spine instability).

Reference: 1. Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. *Mol Genet Metab*. 2013;109(1):54-61. doi:10.1016/j.ymgme.2013.01.021.